Skip to content

Trial Summary

This study aims to assess a new cancer drug, GRWD5769, in patients with advanced cancer.



ACTRN/NCT /ethics:


Scientific title:

A modular, multi-part, multi-arm, open-label, Phase I/II Study to evaluate the safety and tolerability of GRWD5769 in patients with solid malignancies – Module 1.

Sponsor / Cooperative group:

Grey Wolf Therapeutics Pty Ltd

Trial & Patient Characteristics

Cancer TypeAll
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2023-03-20
Anticipated End DateN/A

Participating Hospitals

HospitalSouthern Oncology Clinical Research Unit
Clinical Trial CoordinatorMeggan O'Riley
Phone0491 679 039
Principal InvestigatorGanessan Kichenadasse
Recruitment StatusRecruiting